Monash IVF Group Limited

ASX:MVF Stock Report

Market Cap: AU$444.2m

Monash IVF Group Valuation

Is MVF undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MVF when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MVF (A$1.13) is trading below our estimate of fair value (A$5.12)

Significantly Below Fair Value: MVF is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MVF?

Key metric: As MVF is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MVF. This is calculated by dividing MVF's market cap by their current revenue.
What is MVF's PS Ratio?
PS Ratio1.7x
SalesAU$255.23m
Market CapAU$444.18m

Price to Sales Ratio vs Peers

How does MVF's PS Ratio compare to its peers?

The above table shows the PS ratio for MVF vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.5x
PSQ Pacific Smiles Group
1.7x7.2%AU$311.2m
REG Regis Healthcare
1.9x7.9%AU$1.9b
RHC Ramsay Health Care
0.5x4.4%AU$8.7b
CAJ Capitol Health
1.7x6.4%AU$399.8m
MVF Monash IVF Group
1.7x6.4%AU$444.2m

Price-To-Sales vs Peers: MVF is expensive based on its Price-To-Sales Ratio (1.7x) compared to the peer average (1.5x).

Price to Sales Ratio vs Industry

How does MVF's PS Ratio compare vs other companies in the AU Healthcare Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
FCG Freedom Care Group Holdings
0.1xn/aUS$2.61m
HHI Health House International
0.05xn/aUS$590.30k
TTB Total Brain
0.03xn/aUS$179.68k
No more companies available in this PS range
MVF 1.7xIndustry Avg. 1.5xNo. of Companies3PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MVF is expensive based on its Price-To-Sales Ratio (1.7x) compared to the Oceanic Healthcare industry average (1.5x).

Price to Sales Ratio vs Fair Ratio

What is MVF's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MVF PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.7x
Fair PS Ratio1.2x

Price-To-Sales vs Fair Ratio: MVF is expensive based on its Price-To-Sales Ratio (1.7x) compared to the estimated Fair Price-To-Sales Ratio (1.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MVF forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$1.13
AU$1.52
+34.7%
10.8%AU$1.85AU$1.25n/a7
Nov ’25AU$1.17
AU$1.52
+30.1%
10.8%AU$1.85AU$1.25n/a7
Oct ’25AU$1.25
AU$1.49
+19.4%
11.5%AU$1.85AU$1.25n/a8
Sep ’25AU$1.21
AU$1.49
+23.9%
11.5%AU$1.85AU$1.25n/a8
Aug ’25AU$1.38
AU$1.56
+13.1%
8.8%AU$1.75AU$1.29n/a7
Jul ’25AU$1.25
AU$1.54
+23.8%
7.5%AU$1.70AU$1.29n/a8
Jun ’25AU$1.42
AU$1.54
+8.5%
7.5%AU$1.70AU$1.29n/a8
May ’25AU$1.46
AU$1.54
+5.9%
7.5%AU$1.70AU$1.29n/a8
Apr ’25AU$1.45
AU$1.53
+5.7%
8.2%AU$1.70AU$1.29n/a7
Mar ’25AU$1.44
AU$1.57
+8.8%
5.4%AU$1.70AU$1.45n/a6
Feb ’25AU$1.44
AU$1.48
+2.8%
3.2%AU$1.55AU$1.40n/a6
Jan ’25AU$1.30
AU$1.47
+13.0%
2.7%AU$1.50AU$1.40n/a7
Dec ’24AU$1.30
AU$1.42
+9.2%
5.8%AU$1.50AU$1.29n/a6
Nov ’24AU$1.30
AU$1.32
+1.7%
8.8%AU$1.50AU$1.09AU$1.177
Oct ’24AU$1.26
AU$1.32
+4.9%
8.8%AU$1.50AU$1.09AU$1.257
Sep ’24AU$1.26
AU$1.33
+5.7%
8.4%AU$1.50AU$1.09AU$1.218
Aug ’24AU$1.22
AU$1.32
+7.9%
8.5%AU$1.50AU$1.09AU$1.388
Jul ’24AU$1.15
AU$1.32
+15.5%
8.2%AU$1.50AU$1.09AU$1.258
Jun ’24AU$1.15
AU$1.32
+15.2%
8.8%AU$1.50AU$1.09AU$1.427
May ’24AU$1.16
AU$1.32
+14.2%
8.8%AU$1.50AU$1.09AU$1.467
Apr ’24AU$1.07
AU$1.31
+22.7%
9.7%AU$1.50AU$1.05AU$1.457
Mar ’24AU$1.05
AU$1.31
+25.6%
9.7%AU$1.50AU$1.05AU$1.447
Feb ’24AU$1.08
AU$1.28
+18.2%
8.5%AU$1.40AU$1.05AU$1.447
Jan ’24AU$0.95
AU$1.28
+33.7%
8.5%AU$1.40AU$1.05AU$1.307
Dec ’23AU$0.98
AU$1.26
+28.1%
9.3%AU$1.40AU$1.05AU$1.307
Nov ’23AU$0.93
AU$1.26
+35.5%
9.8%AU$1.43AU$1.05AU$1.307

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.02

7D

0%

1Y

22.9%

Doctor Care Anywhere Group

AU$25.7m

Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.

DOC

AU$0.065

7D

-3.0%

1Y

32.7%

Nova Eye Medical

AU$36.6m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.16

7D

3.2%

1Y

14.3%